Drug firm Dr Reddy's Laboratories on Monday said it has launched in the US Sodium Nitroprusside injection used for immediate reduction of blood pressure in hypertensive crises.
The company has launched generic Sodium Nitroprusside injection, 50 mg/2 ml (25 mg/ml) single-dose vial after getting approval from the United States Food and Drug Administration (USFDA), Dr Reddy's Labs said in a filing to the BSE.
The product is a generic version of Hospira Inc's Nitropress injection, 50 mg/2ml, it added.
As per IQVIA Health data, Nitropress brand and generics had US sales of around USD 8 million MAT for the twelve months to October 2019, Dr Reddy's said.
Sodium Nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises.
Shares of Dr Reddy's Laboratories were trading at Rs 2,902 per scrip on the BSE, up 0.25 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app